Discover how both heat and cold can impact psoriatic arthritis symptoms and learn which is best for your relief.

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc. and Janssen Sciences Ireland ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Etanercept, a TNF inhibitor, is the only FDA-approved therapy for PsA. Other therapies used for PsA are largely based on treatments for other immune-mediated diseases. Perhaps because the ...